Empresa

For immediate release: February 7, 2011

Media Contact: Joan Campion (212) 733-2798 Investor Contact: Jennifer M. Davis (212) 733-0717

Pfizer To Acquire Ferrosan’s Consumer Healthcare Business - - Builds on Pfizer’s Strength in Dietary Supplements; Expands the Portfolio with New Products and New Markets NEW YORK, N.Y., February 7 - Pfizer Inc. (NYSE:PFE) today announced that it has entered into a definitive agreement to purchase Ferrosan’s consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited. Based in Copenhagen, Ferrosan is an innovative and longestablished consumer healthcare company in the Nordic region with a portfolio of leading brands. Since 1920, Ferrosan has grown to serve a broader market including Russia, the Ukraine, Poland, Turkey and many countries throughout Central and Eastern Europe. “Ferrosan is an excellent strategic fit that strengthens our presence in dietary supplements with a new set of compelling brands and product pipeline,” said Paul Sturman, president, Pfizer Consumer Healthcare. Pfizer’s global footprint. “The transaction will mark an As an immediate result of this important step towards expanding Ferrosan’s brands through acquisition, we will gain greater distribution and scale for Pfizer’s well-known brands such as Centrum® and Caltrate® in Ferrosan’s regions.” -more-

-2  Ferrosan’s portfolio of products include Multi-tabs®, a popular multivitamin brand, Bifiform® , a leading probiotic, Fri Flyt/Active Omega, an Omega 3 product, and IMEDEEN® premium oral skincare brands. These Ferrosan brands are among the top-selling products in their respective categories. Ola Erici, President of Ferrosan, said, “We are very pleased that Ferrosan’s innovative portfolio of leading brands will be joining Pfizer. We expect that, as part of the Pfizer portfolio, our And, at the products will build on their industry-leading positions and become available in more countries around...